While most of pharma tries to convince the world that R&D is the number-one priority, one specialty company boasts that it has no lab.
Jun 1, 2006
By:
Sara Calabro
Under King's old strategy, there was no link between business opportunity and R&D. Today, the company only goes after drugs that meet the criteria of its targeted approach to acquisition.
|
|
Genzyme put patients first, and grew to become a multi-billion-dollar company. But empires don't survive on altruism.
Mar 1, 2006
By:
Sara Calabro
Genzyme has an impressive international record in regions with intact healthcare systems. but so far, algeria is one of very few countries where genzyme's drugs have gone from free to paid for. the company is basing a huge investment on faith.
|
|
Nov 1, 2005
By:
Sara Calabro
Valeant is banking on Viramidine, a pro-drug of its longtime cash cow, ribavirin, to catapult the company to the next level.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
